戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e hydrogenation of alpha-keto esters such as ethyl pyruvate.
2                  When mice were treated with ethyl pyruvate (40 mg/kg intraperitoneally every 6 hrs f
3 ts to possible adsorption changes induced by ethyl pyruvate, a common reactant in chiral hydrogenatio
4 te pancreatitis, the same dosing regimen for ethyl pyruvate also ameliorated bacterial translocation
5                               Treatment with ethyl pyruvate ameliorated the local inflammatory respon
6 r outcomes were obtained with the functional ethyl pyruvate analogue 2-acetamidoacrylate.
7   Lipid A analog, phospholipid emulsion, and ethyl pyruvate are currently being evaluated for potenti
8 y providing a compelling basis to reposition ethyl pyruvate as a low-cost immunochemotherapy for clin
9  potential were hepatocyte growth factor and ethyl pyruvate, because they seem to protect against or
10 bility to interfere with NF-kappaB function, ethyl pyruvate blocks IDO induction both in vitro and in
11                               Treatment with ethyl pyruvate decreased pancreatic expression of tumor
12 e that the low-cost, anti-inflammatory agent ethyl pyruvate elicits a potent immune-based antitumor r
13  antagonism with glycyrrhizic acid (Gly) and ethyl pyruvate (EP) did not affect postischemic AKI but
14                 Recent studies indicate that ethyl pyruvate (EP) exerts anti-inflammatory properties;
15                                              Ethyl pyruvate (EP) has pharmacologic effects that remed
16  to evaluate the anti-inflammatory effect of ethyl pyruvate (EP) in a mouse model of lipopolysacchari
17           Our previous studies indicate that ethyl pyruvate (EP) inhibits tumor necrosis factor (TNF)
18                                              Ethyl pyruvate (EP) recently was identified as an experi
19                                              Ethyl pyruvate (EP) treatment inhibits nuclear factor (N
20 f this study was to test the hypothesis that ethyl pyruvate (EP), a soluble pyruvate derivative, is e
21                                              Ethyl pyruvate (EP), an off-the-shelf agent, appears to
22 t for the substitution of either pyruvate or ethyl pyruvate for lactate, respectively.
23 oxidative and ageing aroma compounds such as ethyl pyruvate, furfural or dioxanes in higher concentra
24 so been promising research results involving ethyl pyruvate, glycogen synthase kinase-3 inhibitors an
25                                              Ethyl pyruvate has been shown to be an effective anti-in
26                                              Ethyl pyruvate has been shown to improve cardiac functio
27                               Treatment with ethyl pyruvate has been shown to improve survival and am
28                                              Ethyl pyruvate has been tested in human volunteers and s
29                                     Although ethyl pyruvate has undergone early-phase clinical testin
30               Its pharmacological precursor, ethyl pyruvate, has shown anti-inflammatory/anti-tissue
31 rent that certain pyruvate esters, including ethyl pyruvate, have pharmacological effects, such as su
32 ory formulated a derivative of pyruvic acid, ethyl pyruvate, in a calcium- and potassium-containing b
33                                              Ethyl pyruvate is a simple derivative of the endogenous
34                                              Ethyl pyruvate is a simple molecule that has been shown
35 en mice were treated with a 40 mg/kg dose of ethyl pyruvate just before the first dose of cerulein an
36  cytoplasmic translocation by agents such as ethyl pyruvate limits starvation-induced autophagy.
37 r volumes of either pyruvate (n = 6 each) or ethyl pyruvate (n = 9) solution made up exactly like lac
38 ansfection or inhibition of HMGB1 release by ethyl pyruvate or other small molecules led predominantl
39  1,2-addition of an alphaC-lithiated O-silyl ethyl pyruvate oxime to benzoquinone, which is followed
40 e reaction of 2'-O-aminoribonucleosides with ethyl pyruvate results in the formation of stable 2'-O-i
41 n mice with a noncytotoxic dosing regimen of ethyl pyruvate shown previously to protect against letha
42                               Treatment with ethyl pyruvate solution also significantly decreased the
43                      Treatment with Ringer's ethyl pyruvate solution ameliorated structural and funct
44 quent studies, we showed that treatment with ethyl pyruvate solution could improve survival in rodent
45 ent with either Ringer's lactate solution or ethyl pyruvate solution on several physiologic and bioch
46 ent of rats with either pyruvate solution or ethyl pyruvate solution significantly ameliorated the de
47                                              Ethyl pyruvate solution warrants further evaluation as a
48             Treatment of cholangiocytes with ethyl pyruvate suppressed the release of HMGB1.
49 ell-dependent immunity and IDO targeting for ethyl pyruvate to achieve antitumor efficacy.
50   Since rodents, but not humans, can convert ethyl pyruvate to pyruvate in blood plasma, this additio
51  findings that IDO is effectively blocked by ethyl pyruvate treatment deepen emerging links between I
52 stituted 2-methylquinolines with diacetyl or ethyl pyruvate, under environmentally friendly condition
53                                    Recently, ethyl pyruvate was also shown to improve survival in mur
54                                              Ethyl pyruvate was ineffective at suppressing tumor outg
55                                              Ethyl pyruvate was shown to ameliorate some of the struc
56 ht to determine whether a simple derivative, ethyl pyruvate, would be protective in an animal model o